NovoCure Nears Profitability as Revenue Continues to Soar
NovoCure (NASDAQ: NVCR), a medical device company focused on oncology, reported its second-quarter results on Wednesday.
Revenue growth continues to remain strong and came in at 41% for the period. The sales leverage helped expand its gross margin, enabling the company to significantly reduce its bottom-line loses and produce operating income for the first time.
Metric
Quelle Fool.com